{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:30:55Z","timestamp":1773095455956,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Nordic Cancer Union and Lions Uppsala"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.leukres.2020.106310","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T11:23:00Z","timestamp":1579778580000},"page":"106310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy"],"prefix":"10.1016","volume":"90","author":[{"given":"Stina","family":"S\u00f6derlund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Persson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Ilander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2020.106310_bib0005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106310_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2020.106310_bib0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2020.106310_bib0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2020.106310_bib0025","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2020.106310_bib0030","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2020.106310_bib0035","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106310_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106310_bib0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Schutz","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2020.106310_bib0050","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2020.106310_bib0055","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106310_bib0060","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3109\/10428194.2015.1132420","article-title":"Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients","volume":"57","author":"Smirnikhina","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2020.106310_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-016-0293-y","article-title":"Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients","volume":"9","author":"Caocci","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2020.106310_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2016.09.019","article-title":"Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli","volume":"50","author":"Soderlund","year":"2016","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2020.106310_bib0075","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.leukres.2020.106310_bib0080","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2307\/2529876","article-title":"Random-effects models for longitudinal data","volume":"38","author":"Laird","year":"1982","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.leukres.2020.106310_bib0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to MultipleTesting","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc."},{"issue":"13","key":"10.1016\/j.leukres.2020.106310_bib0090","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106310_bib0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12892","article-title":"How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia","volume":"166","author":"Ross","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106310_bib0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/gene.2011.9","article-title":"LIF in the regulation of T-cell fate and as a potential therapeutic","volume":"12","author":"Metcalfe","year":"2011","journal-title":"Genes Immun."},{"issue":"10","key":"10.1016\/j.leukres.2020.106310_bib0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/carcin\/bgv108","article-title":"LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase\/AKT pathway","volume":"36","author":"Luo","year":"2015","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.leukres.2020.106310_bib0110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3892\/or.2016.4865","article-title":"Leukemia inhibitory factor receptor negatively regulates the metastasis of pancreatic cancer cells in vitro and in vivo","volume":"36","author":"Ma","year":"2016","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.leukres.2020.106310_bib0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.leukres.2020.106310_bib0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.leukres.2013.11.012","article-title":"p-Stat3 and bcr\/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy","volume":"38","author":"Sayed","year":"2014","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2020.106310_bib0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J. Exp. Med."},{"issue":"23","key":"10.1016\/j.leukres.2020.106310_bib0130","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1073\/pnas.1405514111","article-title":"IL-15.IL-15Ralpha complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells","volume":"111","author":"Tamzalit","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.leukres.2020.106310_bib0135","article-title":"IL-15 as a potential target in leukemia","volume":"55","author":"Decot","year":"2015","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"issue":"6","key":"10.1016\/j.leukres.2020.106310_bib0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021857","article-title":"CSF-1 receptor signaling in myeloid cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.leukres.2020.106310_bib0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2015.05.008","article-title":"CSF-1\/CSF-1R targeting agents in clinical development for cancer therapy","volume":"23","author":"Ries","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"8","key":"10.1016\/j.leukres.2020.106310_bib0150","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"issue":"6-10","key":"10.1016\/j.leukres.2020.106310_bib0155","article-title":"Control of hematopoietic stem\/progenitor cell fate by transforming growth factor-beta","volume":"13","author":"Fortunel","year":"2003","journal-title":"Oncol. Res."},{"issue":"7","key":"10.1016\/j.leukres.2020.106310_bib0160","article-title":"Transforming growth factorb3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis","volume":"28","author":"Foglia","year":"2000","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2020.106310_bib0165","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2401384","article-title":"The TGF-b type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression","volume":"13","author":"Rooke","year":"1999","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2020.106310_bib0170","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood.V92.7.2461","article-title":"Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD341 cells","volume":"92","author":"Moore","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2020.106310_bib0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1006\/cyto.2000.0666","article-title":"SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients","volume":"12","author":"Tao","year":"2000","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.leukres.2020.106310_bib0180","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood-2003-10-3443","article-title":"Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib","volume":"103","author":"Bono","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2020.106310_bib0185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.21712","article-title":"The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?","volume":"119","author":"Kelemen","year":"2006","journal-title":"Int. J. Cancer Suppl."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:36Z","timestamp":1758934836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":37,"alternative-id":["S0145212620300151"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106310","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106310"}}